



# Lansoprazole reduces renal cyst in polycystic kidney disease via inhibition of cell proliferation and fluid secretion

Jiriporn Nantavishit <sup>a, b</sup>, Varanuj Chatsudthipong <sup>a</sup>, Sunhapas Soodvilai <sup>a, c</sup>  

 Show more


<https://doi.org/10.1016/j.bcp.2018.05.005>

[Get rights and content](#)

## Abstract

Renal cyst development and expansion in autosomal dominant polycystic kidney disease (ADPKD) is mediated by abnormal cyst-lining cell proliferation and fluid accumulation. Liver X receptor (LXR)-activating ligands suppresses renal cyst enlargement by modulation of cystic fibrosis transmembrane conductance regulator (CFTR)-mediated fluid accumulation. Lansoprazole has been reported as agonist of LXR, and shows an anti-proliferative effect in cancer cells. Here, lansoprazole's pharmacological effect and underlying mechanism on renal cyst development and expansion in *in vitro*; human ADPKD cyst-lining epithelial cell line and Type I Mardin Darby Canine Kidney (MDCK) cells, and *in vivo* models was investigated. Lansoprazole inhibited cyst development via inhibition of cell proliferation. In renal cells, lansoprazole's anti-proliferative effect was mediated by inhibition of mTOR/S6K and extracellular signal-regulated kinase (ERK) signaling proteins. In addition, lansoprazole inhibited CFTR-mediated fluid secretion via reduction of CFTR protein expression. In PCK rats, administering lansoprazole (50mg/kgBW) for 4weeks produced significant decreases in the cystic area and improved renal function by reduction of plasma creatinine and blood urea nitrogen. Inhibition of mTOR/S6K, ERK, and CFTR protein expression was observed in PCK rat kidney following lansoprazole treatment. The findings point to potential therapeutic application of lansoprazole in ADPKD.

## Graphical abstract



[Download high-res image \(76KB\)](#)

[Download full-size image](#)

[Previous](#)

[Next](#)

## Keywords

Polycystic kidney disease; Fluid secretion; Liver X receptor; mTOR; Extracellular signal-regulated kinases; CFTR

[Recommended articles](#)

[Citing articles \(1\)](#)

[View full text](#)

© 2018 Elsevier Inc. All rights reserved.

**ELSEVIER**

[About ScienceDirect](#) [Remote access](#) [Shopping cart](#) [Advertise](#) [Contact and support](#) [Terms and conditions](#)  
[Privacy policy](#)

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the [use of cookies](#).

Copyright © 2019 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.

**RELX™**